Billionaire Bill Gates Dumps $2,228,403,000 in Microsoft and Warren Buffett’s Berkshire Hathaway
Bill Gates is unloading billions of dollars in shares of the company he co-founded, Microsoft (MSFT), while reducing a significant portion of his stake in Warren Buffett’s Berkshire Hathaway (BRK-B).
The 13F filing of the Gates Foundation Trust shows that Gates sold 1,500,000 MSFT shares, valued at $1.04 billion, in Q4 of 2025.
The move trimmed the foundation’s Microsoft holdings from 9,191,207 shares in Q3 to 7,691,207 by the next quarter, representing a 16% decline. As of December 31st, the Gates Foundation Trust’s MSFT ownership stands at $3.719 billion.
The foundation also dumped $1.187 billion worth of Berkshire Hathaway shares in Q4, cutting its position by 2,358,460 BRK-B shares. At the end of Q4 2025, the Gates Foundation Trust owns 19,406,764 BRK-B shares valued at $9.754 billion.
On top of selling portions of its MSFT and BRK-B stakes, the Gates Foundation Trust did not unload any of its other holdings. It also did not accumulate or add to any of its existing positions.
Looking at the foundation’s portfolio, Berkshire Hathaway remains at the top, even after the massive sale, accounting for 27.59% of its total holdings. Coming in at number two is the environmental services provider Waste Management (WM), allocating 17.98% of its portfolio to WM. Other major holdings in the foundation’s portfolio include the Canadian National Railway Company (CNR.TO), Microsoft and Caterpillar (CAT) at 14.49%, 10.52% and 10.29%, respectively.
The Gates Foundation Trust currently oversees over $35 billion in securities.
Generated Image: Midjourney
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
"Predicting Your Prediction" Intensifies Tech Stock Sell-off! After $2.3 Trillion Market Value Evaporates, Has the "Hot Money" Mechanical Selling Still Not Subsided?
The Nasdaq 100 Index fell by 6.4%, wiping out $2.3 trillion in market capitalization. The core reason behind this decline is concerns that a comprehensive victory by the Democratic Party could lead to stricter regulations on AI development. Systematic funds, which typically follow the stock market's trend and respond to price fluctuations and momentum signals, were thus forced to reduce their investments, accelerating the downturn. The selling pressure from systematic strategies may not be over yet; it is expected that in the coming days, portfolios targeting volatility will sell at least $50 billion worth of stocks.
The midterm election tears open the "abyss" of AI trading, facing a moment of reckoning for trillion-dollar capital expenditure narratives
For months, investors have been worried about a series of risks behind the AI (artificial intelligence) capital expenditure "money tree." This week, the market finally pressed the panic selling button.
Crypto prices
More
